Inactive Instrument

News Bionomics Australian S.E.

Stocks

BNO

AU000000BNO5

Biotechnology & Medical Research

All News

06-26	Neuphoria Confirms Business Combination Talks With Scancell	MT
06-26	Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc	AQ
05-15	Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
02-17	Neuphoria Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
01-08	Neuphoria Therapeutics Inc. Announces Termination of Spyridon Papapetropoulos as CEO and Appointment as Interim CEO Effective December 31, 2025	CI
01-08	Neuphoria Therapeutics Inc. Announces Executive Changes Effective January 1, 2026	CI
12-17	Declaration of Voting Results by Neuphoria Therapeutics	CI
12-17	Neuphoria Therapeutics Inc. Approves Appointment of Stephen Doberstein and Kimberly Smith as Class I Directors for A Three-Year Term	CI
12-08	Institutional Shareholder Services Recommends Shareholders of Neuphoria to Vote for its Director Nominees	CI
12-08	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees	AQ
12-04	Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium	RE
12-04	Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium	AQ
12-02	Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics	CI
12-02	Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement	CI
12-01	Neuphoria Therapeutics Issues a Statement in Response to Lynx1 Fictions	CI
12-01	Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions	AQ
11-25	Lynx1 Capital Management Solicits Proxies from Shareholders of Neuphoria Therapeutics	CI
11-24	Neuphoria Therapeutics Sends Letter to Stockholders	CI
11-24	Neuphoria Therapeutics Inc. Sends Letter to Stockholders	AQ
11-18	Lynx1 Capital Sends a Letter to Neuphoria Therapeutics Board	CI
11-14	Lynx1 Capital Management Solicits Proxies from Shareholders of Neuphoria Therapeutics	CI
11-14	Neuphoria Therapeutics may offer & sell common stock of up to $20 million from time to time - SEC filing	RE
11-14	Neuphoria Therapeutics Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025	CI
11-12	Neuphoria Files a Preliminary Proxy Statement with Securities and Exchange Commission	CI
11-11	Neuphoria Announces Receipt of Nomination Notice from Lynx1 Master	CI